We just received data on a new analyst forecast for $KALV. Serge Belanger from Needham set a price target of 32.0 for KALV.
To track analyst ratings and price targets for $KALV, check out Quiver Quantitative's $KALV forecast page.
Should you buy $KALV?
Some analysts are better than others. To view the past performance of Needham, check out Quiver’s Analyst Ratings dashboard. You can also see Quiver’s Analyst Buys Strategy, which uses a proprietary method to track the companies being recommended by the top Wall Street analysts.
$KALV Price Targets
Multiple analysts have issued price targets for $KALV recently. We have seen 4 analysts offer price targets for $KALV in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Serge Belanger from Needham set a target price of $32.0 on 01/06/2026
- Jonathan Wolleben from Citizens set a target price of $28.0 on 11/11/2025
- Jonathan Wolleben from JMP Securities set a target price of $28.0 on 09/12/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $27.0 on 07/11/2025
$KALV Insider Trading Activity
$KALV insiders have traded $KALV stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $KALV stock by insiders over the last 6 months:
- BENJAMIN L PALLEIKO (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 8 sales selling 81,650 shares for an estimated $1,206,540.
- CHRISTOPHER YEA (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 6 sales selling 44,229 shares for an estimated $664,189.
- PAUL K. AUDHYA (CHIEF MEDICAL OFFICER) has made 0 purchases and 5 sales selling 16,588 shares for an estimated $224,768.
- NICOLE SWEENY (Chief Commercial Officer) has made 0 purchases and 3 sales selling 7,157 shares for an estimated $95,797.
- BRIAN PIEKOS (Chief Financial Officer) sold 4,471 shares for an estimated $60,139
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KALV Hedge Fund Activity
We have seen 79 institutional investors add shares of $KALV stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP removed 3,925,000 shares (-84.0%) from their portfolio in Q3 2025, for an estimated $47,806,500
- MILLENNIUM MANAGEMENT LLC added 1,755,594 shares (+515.4%) to their portfolio in Q3 2025, for an estimated $21,383,134
- GOLDMAN SACHS GROUP INC added 1,665,783 shares (+1239.4%) to their portfolio in Q3 2025, for an estimated $20,289,236
- PARKMAN HEALTHCARE PARTNERS LLC added 1,055,940 shares (+155.5%) to their portfolio in Q3 2025, for an estimated $12,861,349
- AMERIPRISE FINANCIAL INC removed 909,676 shares (-96.2%) from their portfolio in Q3 2025, for an estimated $11,079,853
- FREESTONE GROVE PARTNERS LP added 704,448 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,580,176
- SIO CAPITAL MANAGEMENT, LLC added 683,819 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,328,915
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
